Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

    Recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Belgium Czechia France Germany Greece +3
  • Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

    Recruiting

    4 1 1 1
    Investigated Drugs:
    Denmark France Greece Italy The Netherlands Spain +1
  • Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

    Recruiting

    3 1 1
    Investigated Drugs:
    France Germany Greece Italy The Netherlands Poland +1
  • Rifabutin plus drug combination for adult patients with hospital‑acquired and ventilator‑associated pneumonia caused by carbapenem‑resistant Acinetobacter baumannii

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Croatia Greece
  • Study of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease

    Recruiting

    2 1 1
    Investigated Drugs:
    Belgium Germany Hungary Italy Poland
  • Study of mirikizumab versus azathioprine in newly diagnosed moderate-to-severe Crohn’s disease patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    Germany
  • Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Austria Belgium Czechia Denmark Finland France +8
  • Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

    Recruiting

    3 1 1 1
    Germany
  • Discontinuation of methotrexate (drug combination) in rheumatoid arthritis patients using TNF inhibitors

    Recruiting

    3 1 1 1
    The Netherlands
  • Long‑term immunity after a 6‑month‑old MMR vaccine (live attenuated) in infants: follow‑up of antibody levels 1‑3 years after routine vaccination

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Denmark